Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)

US National Institutes of Health (NIH) grant open #PAR-25-153

Response due Sep 07, 2026 · 00:00 UTC

Summary

The National Institutes of Health (NIH) is soliciting R01 research grant applications focused on assay development and screening activities aimed at discovering chemical probes, drugs, or immunomodulators. Clinical trials are explicitly excluded from the scope of this funding opportunity. The program supports early-stage discovery research, including the development and validation of biological assays and high-throughput or targeted screening campaigns. This is a posted Program Announcement with Review (PAR), open for multiple submission cycles between November 2024 and September 2026.

What they want

Technical requirements

Research must involve assay development and/or screening methodologies
Clinical trials are not allowed under this funding opportunity
Must align with R01 grant mechanism requirements

How they evaluate

Submission: Grants.gov federal grants portal (PAR-25-153)

Risks & flags

No dollar value or budget cap stated — award amounts indeterminate from available text
Clinical trials explicitly excluded, which may narrow eligible applicant pools to basic/translational researchers only

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541714

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Assay development and screening for discov…

Due Sep 07

Onboard ↗